Asset Management One Co. Ltd. Has $9.36 Million Stock Holdings in Insulet Corporation $PODD

Asset Management One Co. Ltd. raised its holdings in Insulet Corporation (NASDAQ:PODD) by 7.0% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 29,779 shares of the medical instruments supplier’s stock after purchasing an additional 1,955 shares during the quarter. Asset Management One Co. Ltd.’s holdings in Insulet were worth $9,356,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the business. Sequoia Financial Advisors LLC boosted its holdings in shares of Insulet by 2.3% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 2,017 shares of the medical instruments supplier’s stock valued at $634,000 after purchasing an additional 45 shares in the last quarter. Nissay Asset Management Corp Japan ADV boosted its holdings in shares of Insulet by 0.6% in the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 8,462 shares of the medical instruments supplier’s stock valued at $2,222,000 after purchasing an additional 48 shares in the last quarter. Mather Group LLC. boosted its holdings in shares of Insulet by 4.4% in the 2nd quarter. Mather Group LLC. now owns 1,147 shares of the medical instruments supplier’s stock valued at $360,000 after purchasing an additional 48 shares in the last quarter. Brooklyn Investment Group boosted its holdings in shares of Insulet by 7.0% in the 1st quarter. Brooklyn Investment Group now owns 795 shares of the medical instruments supplier’s stock valued at $209,000 after purchasing an additional 52 shares in the last quarter. Finally, Cooper Financial Group boosted its holdings in shares of Insulet by 5.7% in the 1st quarter. Cooper Financial Group now owns 1,079 shares of the medical instruments supplier’s stock valued at $283,000 after purchasing an additional 58 shares in the last quarter.

Insulet Stock Up 1.5%

Shares of NASDAQ:PODD opened at $325.80 on Tuesday. The firm has a market cap of $22.93 billion, a P/E ratio of 99.03, a P/E/G ratio of 2.68 and a beta of 1.40. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. Insulet Corporation has a 12-month low of $227.03 and a 12-month high of $353.50. The business has a fifty day simple moving average of $327.65 and a 200 day simple moving average of $305.54.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business had revenue of $649.10 million during the quarter, compared to analyst estimates of $612.31 million. During the same period last year, the company earned $0.55 EPS. Insulet’s revenue for the quarter was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Analysts predict that Insulet Corporation will post 3.92 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on PODD shares. Oppenheimer raised their target price on Insulet from $324.00 to $365.00 and gave the company an “outperform” rating in a report on Monday, September 8th. Wall Street Zen raised Insulet from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Jefferies Financial Group reissued a “buy” rating on shares of Insulet in a report on Thursday, August 7th. Rothschild & Co Redburn raised their price objective on Insulet from $350.00 to $370.00 and gave the company a “buy” rating in a report on Friday, October 3rd. Finally, Royal Bank Of Canada raised their price objective on Insulet from $350.00 to $365.00 and gave the company an “outperform” rating in a report on Friday, October 10th. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $352.11.

Insider Activity

In other news, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the transaction, the senior vice president directly owned 3,890 shares of the company’s stock, valued at approximately $1,356,870.90. This trade represents a 17.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Prem Singh sold 687 shares of Insulet stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the transaction, the senior vice president directly owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.39% of the company’s stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.